Ir para o conteúdo principal

BioRestorative Therapies (NASDAQ: BRTX) — Perfil da empresa, notícias e dados financeiros

Logo de BioRestorative Therapies
BRTX BioRestorative Therapies
BioRestorative Therapies primary media
Perfil da empresa

BioRestorative Therapies

BioRestorative Therapies (NASDAQ:BRTX) focuses on developing products and therapies using cell and tissue protocols, primarily aimed at addressing unmet medical needs. Their operations cover a broad spectrum of developmental projects, such as innovative treatments for metabolic disorders and disc/spine disease management through their ThermoStem® and brtxDISC™ programs. BioRestorative Therapies’ objective is to pioneer in the sphere of regenerative medicine by advancing these programs to commercial stages, thereby offering new therapeutic options to patients and the broader healthcare community. With a commitment to scientific excellence and innovation, the company seeks to improve the quality of life for individuals suffering from conditions that currently have limited treatment options.

Resumo

Public USParticipação acionária
1997Ano de fundação
11Funcionários
Melville, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de BioRestorative Therapies

  • ThermoStem is a program using brown adipose tissue-derived stem cells to potentially treat metabolic disorders including diabetes and obesity.
  • BRTX-100 is a product developed for treating chronic lumbar disc disease using a patient's own stem cells.
  • A hair restoration project focuses on developing methods to regenerate hair using stem cell technology.
  • Research in developing biological solutions to repair disc spine without the need for surgical intervention.
  • Engagement in developing therapies for osteoarthritis and other musculoskeletal diseases based on stem cell and tissue engineering techniques.

equipe executiva do BioRestorative Therapies

  • Mika GrassoInterim CEO & Director
  • Anna SkowronCFO & Treasurer
  • Crystal RomanoHead of Global Commercial Operations

Principais indicadores financeiros

Resultados divulgados pela BioRestorative Therapies, em USD.

Cap. de mercado
2,2 mi
Receita (TTM)
357,9 mil
P/L
—
LPA (diluído, TTM)
-21.4
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da BioRestorative Therapies
Fim do ano fiscalReceitaResultado operacionalLucro líquido
359,7 mil-15,6 mi-14,2 mi
401 mil-11,6 mi-9 mi
145,8 mil-15,2 mi-10,4 mi
119,8 mil-18,9 mi-13,2 mi